Efficacy of Sambucol in the Treatment of Influenza
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The trial will examine the efficacy of sambucol in the treatment of influenza. The primary efficacy endpoint will be the length of time to resolution of influenza illness.The double blind trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit, Hadassah University Hospital, and will include 100 patients with laboratory-confirmed influenza infection, 50 in the sambucol and 50 in the placebo study arm.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Fever ≥ 380C.
The presence of at least one of the following respiratory symptoms: cough, sore throat, nasal congestion/ runny nose.
The presence of at least one of the following systemic symptoms: headache, fatigue, myalgia, chills/sweats, malaise.
Pregnant women or women who cannot exclude pregnancy.
Patients with diabetes.
Immune-suppressed patients, including patients taking immunosuppressive drugs.
Patients with renal failure.
Patients who received the recent influenza vaccine.